ABSTRACT. Objective. To evaluate the effects of dietary intake of the long-chain polyunsaturated fatty acids, arachidonic acid (AA), and docosahexaenoic acid (DHA) on multiple indices of infant growth and development.
A re there demonstrable benefits for infant development from feeding infant formulas containing the long-chain polyunsaturated fatty acids arachidonic acid (AA) and docosahexaenoic acid (DHA)? Some studies comparing children who were breastfed (BF) with children who were fed infant formula have reported an association between breastfeeding and intellectual development. [1] [2] [3] [4] In these studies, however, children were not randomized to breast-or formula-feeding, and differences between these cohorts [5] [6] [7] other than diet may explain the findings. For example, parents of BF infants often have a higher socioeconomic status and more years of education, 6 and lifestyle choices known to affect cognitive development, such as cigarette smoking, may differ. 7 Several studies have evaluated whether supplementing formulas for term 8 -17 or preterm 18 -21 infants with DHA or both AA and DHA increases the circulating levels of these fatty acids and enhances visual and cognitive development. Although infants fed human milk or formulas supplemented with DHA or AA and DHA consistently have higher plasma and red blood cell levels of DHA or AA and DHA than infants fed unsupplemented formulas, findings of differences on visual and cognitive tests have been inconsistent in the studies with term infants. Associations between higher levels of DHA in plasma or red blood cells and enhanced visual and cognitive development, thus, have not been established. Unfortunately, these comparisons have likewise been confounded by uncontrolled variation in sample size, differences in formula composition (eg, amounts and ratios of the essential dietary fatty acids [linoleic acid, ␣-linolenic acid] or other nutrients [iron] ), the source of DHA-and AA-enriched fats or oils studied, the amounts and ratios of DHA and AA, the tests and testing procedures used to evaluate child visual and developmental status, and the age(s) at which children have been tested. 22 Infants can form AA and DHA from their essential dietary fatty acid precursors, linoleic acid and ␣-linolenic acid, [23] [24] [25] which are present in formulas but in varying amounts. Therefore, it is plausible that AAand DHA-supplementation may not be necessary in the infant diet. Evidence has been published 11,12,26 -28 suggesting that formulas containing a minimum of 1.75% fatty acids as ␣-linolenic acid and a ratio of linoleic to ␣-linolenic acids of 5:1 to 15:1 may adequately support visual and cognitive development, despite lower circulating levels of AA and DHA.
We conducted a comprehensive double-masked, randomized, parallel, prospective, and adequately powered multivariate study of infants fed a standard unsupplemented formula or 1 of 2 formulas supplemented with AA and DHA from different sources to help bring clarity to the controversial question about benefits to infant development from dietary supplementation. In comparison with published studies 9 -12 available during the design phase of the trial, the sample size was larger, multiple domains of neurodevelopment were evaluated at multiple timepoints, infant temperament was assessed, and two sources of AA and DHA were studied concurrently. In addition to comparisons among infants fed formula with or without AAϩDHA throughout the first year, the present study also evaluated infants who were BF for the first 3 months after which formula with or without AAϩDHA may have been fed as a supplement to breast milk or as a weaning formula. Comparisons between formula-fed and BF infants are also provided.
METHODS

Participants
This 12-month, double-masked, parallel, prospective feeding study enlisted 2 cohorts of term infants, BF and formula-fed. Infants were recruited from hospitals and pediatric practices at 4 sites in the United States: Kansas City, Missouri; Little Rock, Arkansas; Pittsburgh, Pennsylvania; and Tucson, Arizona. The study was approved by institutional review boards at the respective sites. Infant inclusion criteria included: good health, term status (gestational age 37-42 weeks), either Յ9 days of age (formula groups) or Յ11 days of age and currently BF (BF groups), birth weight Ն2500 g, 5-minute Apgar score Ն7, ability to tolerate a milk-based formula or breast milk, parent or guardian agreement to feed the assigned study formula ad libitum according to the study design, and voluntary written informed consent. Infants were ineligible if they had evidence of significant cardiac, respiratory, ophthalmologic, gastrointestinal, hematologic, or metabolic disease; milk-protein allergy; or a maternal medical history known to have proven adverse effects on the fetus (eg, gestational diabetes if the infant's birth weight was Ն4150 g), tuberculosis, human immunodeficiency virus infection, perinatal infections, or substance abuse. Infants who were small-for-gestational-age (Ͻ10th percentile) and large-for-gestational-age (Ͼ90th percentile) were not excluded. The feeding period was to 12 months of age, and data were collected through 14 months of age.
Formulas
At enrollment, formula-fed infants were randomized to a control formula or 1 of 2 formulas supplemented with DHA and AA: 1) fish oil (Mochida International Co, Ltd, Tokyo, Japan) and fungal oil (Suntory Ltd, Osaka, Japan; fish/fungal) or 2) eggderived triglyceride (egg-DTG, Eastman Chemical Co, Kingsport, TN). All formulas were liquid ready-to-feed formulas with (per L): 14.3 to 15.0 g protein; 72.4 to 74.8 g carbohydrate; 35.9 to 37.2 g fat; and 670 to 694 calories. The protein was from nonfat milk and whey protein concentrate, and the oil blend consisted of high-oleic safflower, coconut, and soy oils with or without the AA-and DHA-enriched oils. The study formulas were indistinguishable in appearance and odor and were coded to mask their identity. All formulas contained the essential dietary fatty acids, ␣-linolenic acid (2% fatty acids) and linoleic acid (20% fatty acids; Table 1) , and met or exceeded nutrient levels established by the American Academy of Pediatrics Committee on Nutrition 29 and regulated by the Infant Formula Act of 1980 as amended in 1986.
The levels of DHA and AA in the supplemented formulas were chosen based on previous studies 10, 11, 30 and are similar to recently published levels in human milk in US women. 31, 32 Infants fed formulas with 0.10 to 0.15 g/100 g (%) fatty acids as DHA and about 0.4% as AA had plasma and red blood cell levels of DHA and AA most closely matching those of BF infants in the United States. 10, 11, 30 In the present study, both supplemented formulas contained DHA and AA at 0.13% and 0.45% fatty acids, respectively (Table 1) . Eicosapentaenoic acid (20:5n-3) was not detectable in the egg-DTG formula and was Յ0.04% in the formula with fish oil (fish/fungal). Nine percent of the fat blend in the egg-DTG formula was egg-DTG. In the fish/fungal formula, 0.7% and 1.7% of the fat blend was fish and fungal oils, respectively. Coconut oil levels were reduced accordingly in both formulas.
Design
Infants in the 3 formula groups were randomized within 9 days after birth. Separate randomization schedules for each site were stratified by gender and were computer-generated using a random permuted blocks algorithm. The study formulas were fed ad libitum as the sole source of nutrition for 4 months and as the exclusive milk beverage to 12 months. Infants in the 2 BF groups were randomized to the control (BF/control) or the AAϩDHA (egg-DTG; BF/AAϩDHA) formulas within 11 days after birth and exclusively BF for at least 3 months. Although not encouraged, a small percentage of BF infants occasionally were fed small amounts of supplemental formula, but this was limited to Ͻ16 oz (480 mL) per week. The assigned study formulas were not provided nor fed until after 3 months of exclusive breastfeeding, and only if the parent(s) chose to provide supplemental formula or to wean to formula feeding. All infants were allowed water ad libitum, solid foods after 4 months of age, and alternate formulas for up to 5 days if recommended by a primary care physician or the investigator.
Study visits after enrollment took place at 1, 2, 4, 6, 9, and 12 months with a mail-in questionnaire at 14 months. A window of Ϯ 5 days was permitted for the first 5 visits; the 12-and 14-month visits had a window of Ϯ 7 days. Infant and family demographic information were obtained at the enrollment visit. Formula disposition records, parental records of formula intake at designated intervals throughout the study, and parent interviews at each study visit were used to encourage and monitor compliance with feeding the assigned study formula or human milk.
Red Blood Cell Fatty Acid Analysis
The fatty acid composition in plasma and the phosphatidylcholine and phosphatidylethanolamine membrane fractions of red blood cells were determined from a subset of infants (n ϭ 23-41 per feeding group) at the 4-and 12-month visits. Blood (4 mL) was drawn by venipuncture by a physician or registered phlebotomist from infants whose parents agreed to the procedure. Red cells were stored at Ϫ20°C, shipped on dry ice every 2 to 3 months to a central laboratory (Dr S. M. Innis, University of British Columbia, Vancouver, Canada), verified frozen on arrival, and stored at Ϫ70°C until analyzed for fatty acid composition. 26, 30 
Breast Milk Fatty Acids
A sample of breast milk was provided by a subset of mothers who were still exclusively breastfeeding at the 4-month visit (n ϭ 43). After the infant had nursed for about 5 minutes, the mother removed the infant from the breast and expressed a midfeeding sample into a clean infant bottle, transferred ϳ3 mL to a vial, placed it in a sealable plastic vial, and stored in the home freezer until the study visit. The procedures for collection and storage of milk samples were consistent with recommendations by Jensen et al 33 and those reported by others. 31 The human milk samples were stored at Ϫ20°or Ϫ70°C at the study site, shipped on dry ice to a central laboratory (Dr S. M. Innis, University of British Columbia, Vancouver, Canada), verified to be frozen on arrival, and stored at Ϫ70°C before being analyzed for fatty acid composition as described above for red blood cell fatty acids. The methodologies for determining the fatty acid levels in breast milk samples and the infant formulas were similar.
Standardization of Developmental Procedures
Testing and scoring for all developmental measures and clinical procedures were standardized across all sites, and adherence to testing and scoring procedures was monitored throughout the study to assure reliability. Administrators and coders for the developmental testing were trained in proper procedures, had extensive experience in child development, and met certification requirements. All testers were masked to infant feeding groups.
Testers who administered the acuity card procedure were trained and certified (Dr V. Dobson, Tucson, Arizona; Dr L. Mayer, Boston, Massachusetts) before testing infants. Drs Dobson and Mayer conducted site visits during the study to monitor administration and scoring procedures. One hundred eighty-five infants, who represented approximately 1 of every 4 infants in the study plus additional nonstudy infants, were tested by 2 trained testers at each site to determine reliability. Agreement between the first and second tester was within 1 octave for Ն95% of tests and within 0.5 octave for Ն70% of the tests (Kendall's ϭ 0.79; P Ͻ .0001).
Procedures for administration of the Bayley Scales of Infant Development and the Fagan Test were coordinated centrally (Dr R. Arendt, Cleveland, Ohio). A workshop was held to standardize testing procedures (Drs L. Singer, R. Arendt, C. Segal, Cleveland, Ohio), and a videotape of the testing procedures was provided to all testers. Testers who administered the Fagan Test were trained and certified (Drs L. Singer, E. Shaver, Cleveland, Ohio) before testing infants. Approximately 1 out of every 10 Bayley test sessions at the 6-and 12-month time points were videotaped, and the videotapes were scored centrally (Dr R. Arendt, Cleveland, Ohio). The average percent agreement among testers for the Bayley mental index was 77% and 91% at the 6-and 12-months, respectively, and for the Bayley motor index was 87% and 91%, respectively.
Growth
Weight, length, and head circumference were measured at enrollment and 1, 2, 4, 6, 9, and 12 months using standardized procedures (Guide to Growth Assessment of Infants in Clinical Studies 34 ).
Visual Acuity
Visual acuity was assessed using the Teller Acuity Card Procedure (Vistech Inc, Dayton, OH 35 ) at 2, 4, 6, and 12 months. Infants were shown a series of 25.5 ϫ 51-cm cards with black and white stripes varying in spatial frequency (stripe width) by halfoctave steps. One octave is a halving or doubling of spatial frequency. The finest grating (stripe width) to which the infant showed a consistent fixation response is the visual acuity threshold in cycles/degree with the variance (SD) in octaves.
Information Processing
The Fagan Test of Infant Intelligence (Infantest Corporation, Cleveland, OH 36 ) was administered at 6 and 9 months. During a familiarization period, a face stimulus was shown until the infant accumulated a predetermined amount of looking time; during the subsequent test period, the familiar face stimulus was shown concurrently with a novel face stimulus. The amount of looking time spent on each stimulus was recorded (IBM Thinkpad), and "novelty preference" (percentage of total looking time spent looking at the novel stimulus during the test phase averaged across 10 tests) was computed. In addition, mean duration of looking time, construed as a measure of efficiency of information processing, was computed for both the familiarization and test periods by dividing the total looking time by the number of looks averaged across 10 tests. 37, 38 
General Developmental Level
The Bayley Scales of Infant Development (Psychological Corporation, 2nd ed, San Antonio, TX 39 ) were administered at 6 and 12 months to assess motor and cognitive development (Psychomotor Developmental Index; Mental Developmental Index, respectively).
Language
The infant version of the MacArthur Communicative Development Inventories, 40 a standardized parent-report instrument, was completed at 9 and 14 months. This checklist of words, phrases, gestures, and actions provides information about comprehension vocabulary (words and phrases the child understands), and expressive vocabulary (words and phrases the child says). Percentile scores were computed from gender-specific norms and transformed to standard scores by convention.
374
DEVELOPMENT 
, soothability, smiling and laughter, and duration of orienting. Infant temperament was also assessed using the Behavior Rating Scale of the Bayley Scales 39 , an index of the examiner's overall impression of the child's behavior.
Statistical Methods
Power analysis estimated that 54 infants (27 male, 27 female) in each of the 3 randomized formula groups were needed to detect a 1 SD difference in growth for each gender with 90% power. An additional sample size estimate was based on the results of a previous study showing lower vocabulary scores in 14-month-old infants fed a DHA-supplemented formula than in infants fed human milk or a control formula, respectively 12 . This power analysis estimated that 47 infants per group were needed to detect a 0.75 SD difference in vocabulary scores with 90% power. Blood samples from approximately 27 infants per group were needed to detect a 1 SD difference (90% power) in the levels of the fatty acids, AA and DHA.
All analyses controlled for site (ie, site was used as a covariate) to minimize the potential confounding effect of intersite variability. Comparisons among the 3 formula groups and between the 2 BF groups were done twice, once with no additional covariates and once with additional covariates selected a priori. Analyses reported are without the additional covariates; in all cases covariate analyses showed similar results. Categorical variables were analyzed using 2 or Cochran-Mantel-Haenszel tests and continuous variables by analysis of variance (analysis of variance) and/or analysis of covariance. Repeated measures analyses were used for data collected at Ͼ1 time period. Post hoc comparisons of formula-fed and BF infants were done using the BF and corresponding formula groups to provide the greatest power to detect differences between these cohorts.
RESULTS
Two hundred ninety-four (73%) of the 404 enrolled infants completed the study. The most common reasons for exiting the study early were reported intolerance for the formula groups (n ϭ 16, 13, and 14 for the control, egg-DTG, and fish/fungal groups, respectively) and cessation of breastfeeding and/or formula feedings started before 3 months for the BF groups (n ϭ 10 and 9 for the BF/control and BF/ AAϩDHA groups, respectively). The distribution of infants across groups, the primary reasons for early exit, and the numbers of days in the study did not differ across groups for those who exited early.
Infant and family sociodemographic characteristics were not different among the formula groups or between the BF groups, with the exception of inconsequential statistical differences between the BF/control and BF/AAϩDHA groups for infant gestational age (39.2 Ϯ 1.2 vs 39.6 Ϯ 1.3 weeks, respectively) and for maternal age (29.1 Ϯ 5.2 vs 30.8 Ϯ 4.6 years, respectively). The demographic characteristics of the study population as a whole are generally similar to those described for the US population. 42 The average daily caloric intake of formula and measures of formula tolerance (eg, frequency of spitting up and/or vomiting; consistency of stools) did not differ among groups within each cohort (data not shown).
Comparisons between the formula-fed and BF groups showed the formula groups with a larger percentage of mothers having no postsecondary education (39, 33, 21, and 19% in the control, AAϩDHA [egg-DTG], BF/control, and BF/AAϩDHA groups, respectively; P ϭ .024) and a higher prevalence of smoking (Table 2 ). Although breastfeeding rates in the present study declined after 3 months, the rates were higher than the national averages in the mid1990s. In the present study, 36% of mothers were exclusively breastfeeding at 6 months with another 30% providing breast milk for some of the daily feedings. The national breastfeeding rates are about 10% and 15%, respectively, for mothers with similar demographics 43 (AS Ryan, personal communication).
AA and DHA
The average levels of AA and DHA in breast milk at 4 months were 0.51% (range: 0.27%-0.93%) and 0.12% (range: 0.04%-0.34%), respectively. Infants fed the AAϩDHA supplemented formulas, independent of the source (egg-DTG or fish/fungal), had significantly higher levels of AA and DHA in red blood cell phospholipids than those fed the control formula (P Ͻ .0001; Table 3 ). In the BF groups, red blood cell phospholipid levels of AA and DHA were not different at 4 months, but at 12 months infants fed the AAϩDHA formula had about 40% higher levels of DHA than those fed the control formula (P ϭ .03). Comparisons between the BF and corresponding formula groups found lower AA and DHA levels in red blood cells of infants fed the unsupplemented control formula than those fed the supplemented formula and/or human milk (Table 3) .
Growth
There were no overall or gender specific differences for increases in weight, length, or head circumference among groups during the 12-month study (Fig 1) . Weight gain from enrollment to 12 months was 17.7 Ϯ 2.6, 17.8 Ϯ 2.4, and 17.3 Ϯ 2.6 g/d (P Ͼ .05) for infants fed the control, AAϩDHA (fish/fungal), and AAϩDHA (egg-DTG) formulas and 17.4 Ϯ 2.6. and 18.0 Ϯ 3.1 g/d (P Ͼ .05) for infants in the BF/control and BF/AAϩDHA groups, respectively. Weight gain for male infants between enrollment and 4 months, but not between enrollment and 12 months, was greater for the AAϩDHA (fish/fungal) group than the control group (31.4 Ϯ 4.6 g/d and 27.8 Ϯ 4.2, respectively; P Ͻ .05). Weight gain for infants fed AAϩDHA from egg-DTG (29.1 Ϯ 5.1 g/d) was not greater than the control group over the same period. Similarly, there were no differences in length or head circumference gains between enrollment and 4 months. Gains in weight, length, and head circumference between 0 and 4 months and 0 and 12 months were not different between the BF/ control and BF/AAϩDHA groups. No differences in growth between the BF and corresponding formula groups were found.
Visual Acuity
Visual acuity results (cyc/deg) were log-transformed according to convention 44 before analysis, and the geometric mean values (cyc/deg) are reported with SD in octaves. Visual acuity was in the normal range for each group at all ages tested 45, 46 and was not different in relation to supplementing infant formula with AAϩDHA (Fig 2) . Visual acuity was not different between the BF and corresponding formula groups.
Information Processing
Infant information processing, assessed as novelty preference, was also in the normal range at the 2 ages tested. 36, 47, 48 Scores did not differ between infants in the formula control and AAϩDHA groups or between BF/control and BF/AAϩDHA groups (Table  4) . Look duration during the familiarization and testing periods, thought to index the rate of information processing, 37, 38 similarly did not differ in relation to adding AA and DHA to formula (data not shown). Novelty preference and look duration also were not different between the BF and corresponding formula groups.
Bayley Scales
Infants in all groups scored in the normal ranges on both the psychomotor and mental development indices of the Bayley Scales. 39 Neither index at 6 or 12 months differed among the formula control and the AAϩDHA groups or between the BF/control and BF/AAϩDHA groups (Table 4) . No differences emerged in the percentages of infants who scored Ͻ70 or 71 to 84 (data not shown). There were no differences in mental or motor scales between the BF and corresponding formula groups.
Language
Children scored in the normal range of the vocabulary comprehension and expression at the ages tested. 40 Vocabulary comprehension did not differ among the three formula groups or between the BF groups, but at 14 months, infants fed the AAϩDHA (fish/fungal) formula had a slightly, but significantly, higher vocabulary expression score than those fed the AAϩDHA (egg-DTG) formula (Table  4) . However, neither AAϩDHA group was significantly different from the control formula group, and there were no differences between the BF and corresponding formula groups. LGA, large-for-gestational age (Ͼ90th percentile). † P Ͻ .05. ‡ Other category includes Native American and mixed ethnicities. Significant differences in post hoc comparisons between the breastfed and corresponding formula groups: * P ϭ .006 for gestational age, BF/AAϩDHA (egg/DTG) group versus AAϩDHA (egg-DTG) formula group; § P ϭ .001 for maternal age, BF/AAϩDHA (egg-DTG) group versus control formula group; P ϭ .054 for maternal smoking during pregnancy, breastfed versus formula groups; ¶ P ϭ .001 for prevalence of smoking in the household, breastfed versus formula groups.
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Temperament
No differences emerged among the groups for 5 of the 6 dimensions of the Infant Behavior Questionnaire (Table 4 ). The smiling and laughter score for the control formula group was slightly but statistically significantly higher than for the AAϩDHA (Egg-DTG) formula group. No differences emerged on any score between the BF/control and the BF/ AAϩDHA groups. The percentages of infants with Behavior Rating Scale facet scores (motor quality, orientation/engagement, emotional regulation) on the Bayley Scales at or below the lowest 10th percentile of the reference population did not differ among any groups in relation to AAϩDHA supplementation (data not shown). No differences emerged between the BF and corresponding formula groups on the dimensions of Infant Behavior Questionnaire or on the facet scores of the Bayley Scales.
DISCUSSION
This is the largest randomized, prospective, longitudinal, and multivariate study to compare AAϩDHA-supplemented formulas with an unsupplemented control formula fed to term infants for the first year after birth. Infants in all groups developed normally on multiple indices of development over the first 14 months after birth. AAϩDHA supplementation predictably increased the levels of these fatty acids in plasma and red cells, but multiple measures of growth, visual acuity, information processing, general development, language, and temperament assessed using masked clinical tests and by parent report instruments through 14 months of age were not different among infants who were fed AAϩDHA-supplemented and control formulas. The variance in the visual and developmental tests was not increased with multiple testers at multiple sites, evidence that the sensitivity of the tests was not compromised in this multicenter trial. The variances were those expected 36, 39, 40 with the standard deviations for the visual acuity and Bayley Scales assessments similar to 10,13,16,26 -28 or less than 15, 17 those reported in similar single-center studies. The comparisons in this trial were adequately powered, and the overall patterns of results were the same when covariates with high potential to influence developmental outcomes were included in the statistical models.
The visual and neurodevelopmental results of the present study are consistent with those of a previous study for which the control formula was the same as in this study except that it did not contain added nucleotides. 11, 12 The levels of AA and DHA in milk from women in the present study were also similar to those previously reported by many, 10 -12,31-32 but not all, 13, 16 contemporaneous studies in the United States including samples from Portland, Oregon 31, 32 where DHA levels would be expected to be higher. 49 Furthermore, the demographics of the sample studied here (Table 2) were generally comparable to the Published studies in which formulas containing sources of DHA or both AA and DHA were fed to term infants have reported mixed outcomes in terms of the potential advantages of supplementation. 8 -17 Several explanations for this variance are possible, including differences in the amount of the ␣-linolenic acid (precursor to DHA), the source or amount of the AA-and/or DHA-enriched ingredient (eg, fish oil, egg lipid, algal oil, fungal oil), other differences in formula composition, the outcomes studied, the testing procedures used, the number of months of formula feeding, and/or the number of infants studied. Additionally, the influence of genetic and specific socioenvironmental factors on developmental measures may be greater than previously recognized. 50, 51 This lack of consistency in the extant literature to- Visual acuity measured by the acuity card procedure for infants fed formulas with or without AAϩDHA or BF for at least the first 3 months after which formula with or without AAϩDHA may have been fed as a supplement or weaning formula. A) Formula groups: E, control formula; ▫, AAϩDHA (egg-DTG) supplemented formula. ‚, AAϩDHA (fish/fungal) supplemented formula. B) BF groups: F, BF/control formula; f, BF/AAϩDHA (egg-DTG) supplemented formula. Data are shown on the left axis as mean (cycles/degree; cy/ deg) Ϯ SD (octaves). No differences in visual acuity among groups by repeatedmeasures analysis were found.
gether with the comprehensiveness of the present report casts doubt on any certain advantage of adding DHA and AA to infant formula.
The fact that no consistent differences emerged for any of several diverse measures of infant development and functioning between infants fed the supplemented formulas also suggests that differences in the triglyceride fatty acid distribution between fish and fungal compared with egg-DTG are of little or no consequence, at least for the outcomes studied.
The absence of significant and/or consistent effects of the AAϩDHA formulas on multiple measures of general development, including growth, visual acuity, information processing, language, and temperament over the first 14 months after birth, together with the fact that all assessments, test re- Values are mean Ϯ SD. n ϭ numbers of participants at the designated study visits. Unless otherwise noted, no significant differences were found within the formula-fed or BF groups or between the BF and corresponding formula groups. * Unlike letter notations within the formula-fed groups indicate significantly different Bonferonni adjusted pairwise comparisons (a,b, P Ͻ .05). † A 7-point scale was used; 1 ϭ never, 2 ϭ very rarely, 3 ϭ less than half the time, 4 ϭ about half the time, 5 ϭ more than half the time, 6 ϭ almost always, 7 ϭ always. Comparisons between the BF and corresponding formula groups by repeated-measures analysis found no significant differences with or without adjustment for covariates. ‡ Values were significantly different by repeated-measures analysis with or without adjustments for covariates for the formula control group versus the AAϩDHA (Egg-DTG) group, P ϭ .05.
sults, and variances fell within normal ranges, despite higher AA and twofold increases in red blood cell levels of DHA, point to the conclusion that there would be no demonstrable advantage to infant development from the widespread addition of AAϩDHA to infant formula. This conclusion is further supported by the absence of advantages to breastfeeding on the visual and developmental outcomes tested despite the expected differences in family demographics and red blood cell AA and DHA levels. It may be possible that differences (advantages or disadvantages) of AAϩDHA supplementation do not appear until after the first year, that they may be present in domains of development not measured here, that they only appear in more differentiated and subtle assessments, or that they only become apparent in direct response to cognitive or social stressors. However, at the average levels of AA and DHA in human milk reported in the United States and for common standardized and robust developmental measures, dietary supplementation with AAϩDHA seems to pose no demonstrable benefits for infant development in a study population similar to the overall US population.
